Deniz Uluışık, Ercan Keskin, Durmuş Hatipoğlu

Effects of Melatonin on Some Antioxidant Enzymes in Streptozotocin-induced Diabetic Rats

In this study, it was aimed to determine the effects of melatonin application in experimentally induced diabetes. For thispurpose, thirty two adult male Wistar Albino rats were used. Animals in control group were not any treatment. Melatoningroup animals received 50 mg/kg melatonin intraperitoneally in daily for eight weeks. Diabetes was induced by subcutaneousinjections of streptozotocin at dose of 40 mg/kg for two days as a single dose per day in diabetes group animals. Animals inDiabetes+Melatonin group were made diabetic by streptozotocin in the same way and then these animals received 50 mg/kgmelatonin intraperitoneally in daily for eight weeks. In blood samples taken from all animals, insulin, glucose, HbA1c, MDA,GSH, SOD were determined. The insulin level in diabetes group was lower than control group, while blood glucose level washigher (p

PDF

___

1. Aguirre F, Martin I, Grinspon D, Ruiz M, Hager A, de Paoli T, Ihlo J, Farach HA, Poole CP. Oxidative damage, plasma antioxidant capacity and glucemic control in elderly NIDDM patients-Possible implications for diabetic atherosclerosis. Free Radical Biology and Medicine, 1998; 24(4): 580-585.
2. Aksoy N, Vural H, Sabuncu T, Aksoy S. Effects of melatonin on oxidative-antioxidative status of tissues in streptozotocininduced diabetic rats. Cell Biochemistry and Function, 2003; 21(2): 121-125.
3. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. Journal of Pineal Research, 2003; 34(1): 1-10.
4. Ashour M, Salem S, Hassaneen H, El-Gadban H, Elwan N, Awad A, Basu TK. Antioxidant status and insulin-dependent diabetes mellitus (IDDM). Journal of Clinical Biochemistry and Nutrition, 1999; 26(2): 99-107.
5. A Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes, 1991; 40(4): 405-412.
6. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes, 1999; 48(1): 1-9.
7. Becker-Andre M, Wiesenberg I, Schaeren-Wiemers N, Andre E, Missbach M, Saurat JH, Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of nucleur receptor superfamily. Journal of Biological Chemistry, 1994; 269(46): 28531-28534.
8. Bojunga J, Dresar-Mayert B, Usadel KH, Kusterer K, Zeuzem S. Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. Biochemical and Biophysical Research Communications, 2004; 316(3): 771-780.
9. Brzezinski A. Melatonin in humans. New England Journal of Medicine, 1997; 336(3): 186-195.
10. Ceriello A. Oxidative stress and glycemic regulation. Metabolism, 2000; 49(2): 27-29.
11. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, Ezsol Z, Tonutti L, Taboga C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. European Journal of Clinical Investigation, 1998; 28: 329-333.
12. Chang KC, Chung SY, Chong WS, Suh JS, Kim SH, Noh HK, Seong BW, Ko HJ, Chun KW. Possible superoxide radicalinduced alteration of vascular reactivity in aortas from streptozotocin-treated rats. Journal of Pharmacology and Experimental Therapeutics, 1993; 266(2): 992-1000.
13. Derlacz RA, Poplawski P, Napierala M, Jagielski AK, Bryla J. Melatonin-induced modulation of glucose metabolism in primary cultures of rabbit kidney-cortex tubules. Journal of Pineal Research, 2005; 38(3): 164-169.
14. Donder E, Baydas G, Sokmen S, Ercel E, Yalniz M, Dogan H, Bahçeoğlu IH. Investigation of antioxidant and glucometabolic effects of melatonin in experimental diabetes mellitus. Biomedical Research, 1999; 10(2): 127-32.
15. Espino J, Pariente JA, Rodríguez AB. Role of melatonin on diabetes-related metabolic disorders. World Journal of Diabetes, 2011; 2(6): 82-91.
16. Feillet C, Roche B, Tauveron I, Bayle D, Rock E, Borel P, Rayssiguier Y, Thieblot P, Mazur A. Susceptibility to oxidation and physicochemical properties of LDL in insulindependent diabetics. Atherosclerosis, 1998; 136: 405-407.
17. Ha E, Yim SV, Chung JH, Yoon KS, Kang I, Cho YH, Baik HH. Melatonin stimulates glucose transport via insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway in C2C12 murine skeletal muscle cells. Journal of Pineal Research, 2006; 41(1): 67-72.
18. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods in Enzymology, 1990; 186: 1-85.
19. Kataoka S, Satoh J, Fujiya H, Toyota T, Suzuki R, Itoh K, Kumagai K. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes, 1983; 32(3): 247-253.
20. Kedziora-Kornatowska KZ, Luciak M, Paszkowski J. Lipid peroxidation and activities of antioxidant enzymes in the diabetic kidney: effect of treatment with angiotensin convertase inhibitors. IUBMB Life, 2000; 49(4): 303-307.
21. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic beta cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Molecular and Cellular Endocrinology, 2002; 191(2): 157-166.
22. Klepac N, Rudeš Z, Klepac R. Effects of melatonin on plasma oxidative stress in rats with streptozotocin induced diabetes. Biomedicine and Pharmacotherapy, 2005; 60(1): 32-35.
23. Laight DW, Carrier MJ, Anggard EE. Antioxidants, diabetes and endothelial dysfunction. Cardiovascular Research, 2000; 47: 457-464.
24. Legros C, Devavry S, Caignard S, Tessier C, Delagrange P, Ouvry C, Boutin JA, Nosjean O. Melatonin MT(1) and MT(2) receptors display different molecular pharmacologies only in the G-protein coupled state. British Journal of Pharmacology, 2014; 171(1): 186-201.
25. Like AA, Rossini AA, Guberski DL, Appel MC, Williams RM. Spontaneous diabetes mellitus: Reversal and prevention in the BB/W rat with antiserum to rat lymphocytes. Science, 1979; 206(4425): 1421-1423.
26. Lo CC, Lin SH, Chang JS, Chien YW. Effects of melatonin on glucose homeostasis, antioxidant ability, and adipokine secretion in ICR mice with NA/STZ-induced hyperglycemia. Nutrients, 2017; 9(11): 1187.
27. MacKenzie RS, Melan MA, Passey DK, Witt-Enderby PA. Dual coupling of MT(1) and MT(2) melatonin receptors to cyclic AMP and phosphoinositide signal transduction cascades and their regulation following melatonin exposure. Biochemical Pharmacology, 2002; 63(4): 587-595.
28. Makimattila S, Liu ML, Vakkilainen J, Schlenzka A, Lahdenperä S, Syvänne M, Mäntysaari M, Summanen P, Bergholm R, Taskinen MR, Yki-Järvinen H. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care, 1999; 22(6): 973-981.
29. Malaisse WJ. Alloxan toxicity to pancreatic B-cells. A new hypothesis. Biochemical Pharmacology, 1982; 31(22): 3527- 3534.
30. Maritim AC, Sanders RA, Watkins JB. Diabetes, oxidative stress, and antioxidants: a review. Journal of Biochemical and Molecular Toxicology, 2003; 17(1): 24-38.
31. Maxwell SRJ, Thomason H, Sandler D, LeGuen C, Baxter MA, Thorpe GHG, Jones AF, Barnett AH. Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in Non-Insulin-Dependent Diabetes Mellitus. Annals of Clinical Biochemistry, 1997; 34(6): 638-644.
32. McLennan SV, Heffernan S, Wright L, Rae C, Fisher E, Yue DK, Turtle JR. Changes in hepatic glutathione metabolism in diabetes. Diabetes, 1991; 40(3): 344-348.
33. Mohammed A, Adelaiye AB, Bakari AG, Mabrouk MA. Antidiabetic and some haematological effects of ethylacetate and n-butanol fractions of Ganoderma lucidum aqueous extract in alloxan-induced diabetic wistar rats. International Journal of Medicine and Medical Sciences, 2009; 1(12): 530-535.
34. Mohan IK, Das UN. Oxidant stress, antioxidants and nitric oxide in non-insulin dependent diabetes mellitus. Medical Science Research, 1997; 25: 55-57.
35. Montilla PL, Vargas JF, Tlinez IF, Muñoz de Agueda MC, Valdelvira ME, Cabrera ES. Oxidative stress in diabetic rats induced by streptozotocin: Protective effects of melatonin. Journal of Pineal Research, 1998; 25(2): 94-100.
36. Nishida S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine, 2005; 27: 131-136.
37. Paik SG, Blue ML, Fleischer N, Shin S. Diabetes susceptibility of BALB/cBOM mice treated with streptozotocin. Inhibition by lethal irradiation and restoration by splenic lymphocytes. Diabetes, 1982; 31(9): 808-815.
38. Peschke E. Melatonin, endocrine pancreas and diabetes. Journal of Pineal Research, 2008; 44(1): 26-40.
39. Peschke E, Bahr I, Mühlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. International Journal of Molecular Sciences, 2013; 14(4): 6981-7015.
40. Peschke E, Fauteck JD, Musshoff U, Schmidt F, Beckmann A, Peschke D. Evidence for a melatonin receptor within pancreatic islets of neonate rats: functional, autoradiographic, and molecular investigations. Journal of Pineal Research, 2000; 28: 156-164.
41. Picinato MC, Haber EP, Cipolla-Neto J, Curi R, de Oliveira Carvalho CR, Carpinelli AR. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. Journal of Pineal Research, 2002; 33: 156-160.
42. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomedicine and Pharmacotherapy, 2005; 59: 365-373.
43. Reiter R, Tang L, Garcia JJ, Munoz-Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sciences, 1997; 60(25): 2255-2271.
44. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB Journal, 1995; 9(7): 526-533.
45. Reiter RJ. Melatonin: lowering the high price of free radicals. News in Physiological Sciences, 2000; 15: 246-250.
46. Reiter RJ, Tan DX, Manchester LC, Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochemistry and Biophysics, 2001; 34(2): 237-256.
47. Reunanen A, Knekt P, Aaran RK, Aromaa A. Serum antioxidants and risk of non-insulin dependent diabetes mellitus. European Journal of Clinical Nutrition, 1998; 52: 89- 93.
48. Robertson RP. Chronic oxidative stress: a central mechanism for glucose toxicity in pancreatic islet beta cell in diabetes. Journal of Biological Chemistry, 2004; 279(41): 42351-42354.
49. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, Reiter RJ. Regulation of antioxidant enzymes: a significant role for melatonin. Journal of Pineal Research, 2004; 36(1): 1-9.
50. Sandler S, Andersson AK, Barbu A, Hellerstrom C, Holstad M, Karlsson E, Sandberg JO, Strandell E, Saldeen J, Sternesjo J, Tillmar L, Eizirik DL, Flodström M, Welsh N. Novel experimental strategies to prevent the development of type 1 diabetes mellitus. Upsala Journal of Medical Sciences, 2000; 105(2): 17-34.
51. Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, Scherrer U, Duplain H. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology, 2009; 150(12): 5311-5317.
52. Saxena AK, Srivastava P, Kale RK, Baquer NZ. Impaired antioxidant status in diabetic rat liver. Effect of vanadate. Biochemical Pharmacology, 1993; 45(3): 539-542.
53. Shewade Y, Tirth S, Bhonde RR. Pancreatic islet-cell viability, functionality and oxidative status remain unaffected at pharmacological concentrations of commonly used antibiotics in vitro. Journal of Biosciences, 2001; 26(3): 349-355.
54. Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV, Kubyshin VL, Lapshina EA, Bryszewska M, Reiter RJ, Zavodnik IB. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. European Journal of Pharmacology, 2007; 569(3): 180-187.
55. Sun H, Wang X, Chen J, Song K, Gusdon AM, Li L, Bu L, Qu S. Melatonin improves non-alcoholic fatty liver disease via MAPK-JNK/P38 signaling in high-fat-diet-induced obese mice. Lipids in Health and Diseases, 2016; 15: 202.
56. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species?. Journal of Pineal Research, 2007; 42: 28-42.
57. Tüzün S, Girgin FK, Sözmen EY, Menteş G, Ersöz B. Antioxidant status in experimental type 2 diabetes mellitus: effects of glibenclamide and glipizide on various rat tissues. Experimental and Toxicologic Pathology, 1999; 51(4-5): 436- 441.
58. Willems D, Dorchy H, Dufrasne D. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications. Atherosclerosis, 1998; 137: 61-64.
59. Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. Journal of Pineal Research, 2006; 40(2): 168-176.
60. Wolf SP, Dean RT. Glucose autoxidation and protein modification. The potential role of “autoxidative glycosylation” in diabetes. Biochemical Journal, 1987; 245(1): 243-250.
61. Yavuz O, Cam M, Bukan N, Guven A, Silan F. Protective effect of melatonin on β-cell damage in streptozotocininduced diabetes in rats. Acta Histochemica, 2003; 105(3): 261- 266.
62. Young IS, Tate S, Lightbody JH, McMaster D, Trimble ER. The effects of desferrioxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat. Free Radical Biology and Medicine, 1995; 18(5): 833-840.

Başlangıç: 1999
Yayıncı: Selçuk Üniversitesi, Spor Bilimleri Fakültesi

Arşiv